Abzena, Alira Health, and Oncodesign Launch Specialist Services Consortium
Abzena (Cambridge, UK), Alira Health (Framingham, MA), and Oncodesign (Dijon, France) have announced that, with the launch of DRIVE™-Biologics, they are entering into a consortium to offer their partners “synergy and expertise in their biologics drug discovery and development programs.”
The companies state that their joint service offering will leverage Abzena’s strength in design and developability and cell line development through to commercial manufacturing of biologics, alongside Oncodesign’s pharmacology expertise in oncology and inflammatory diseases, and Alira Health’s full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
“We are delighted to formalize our relationship with Oncodesign and extend it to Alira Health to bring our partners access to therapeutic innovation. Our shared mission to put patients at the center of all that we do means we are continuing to innovate and drive effective therapies to align to the needs of our partners,” commented Campbell Bunce, PhD, Chief Scientific Officer of Abzena.
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.
